|
1
|
Andersen JB, Spee B, Blechacz BR, Avital
I, Komuta M, Barbour A, Conner EA, Gillen MC and Roskams T: Genomic
and genetic characterization of cholangiocarcinoma identifies
therapeutic targets for tyrosine kinase inhibitors.
Gastroenterology. 142:1021–1031.e15. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Banales JM, Cardinale V, Carpino G,
Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes
SJ, Fouassier L, et al: Expert consensus document:
Cholangiocarcinoma: Current knowledge and future perspectives
consensus statement from the European network for the study of
cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol.
13:261–280. 2016. View Article : Google Scholar
|
|
3
|
Strijker M, Belkouz A, van der Geest LG,
van Gulik TM, van Hooft JE, de Meijer VE, Haj Mohammad N, de Reuver
PR, Verheij J, de Vos-Geelen J, et al: Treatment and survival of
resected and unresected distal cholangiocarcinoma: A nationwide
study. Acta Oncol. 58:1048–1055. 2019. View Article : Google Scholar
|
|
4
|
Kamsa-Ard S, Luvira V, Suwanrungruang K,
Kamsa-Ard S, Luvira V, Santong C, Srisuk T, Pugkhem A,
Bhudhisawasdi V and Pairojkul C: Cholangiocarcinoma trends,
incidence, and relative survival in Khon Kaen, Thailand from 1989
through 2013: A population-based cancer registry study. J
Epidemiol. 29:197–204. 2019. View Article : Google Scholar
|
|
5
|
Lindnér P, Rizell M and Hafström L: The
impact of changed strategies for patients with cholangiocarcinoma
in this millenium. HPB Surg. 2015:7360492015. View Article : Google Scholar
|
|
6
|
Alabraba E, Joshi H, Bird N, Griffin R,
Sturgess R, Stern N, Sieberhagen C, Cross T, Camenzuli A, Davis R,
et al: Increased multimodality treatment options has improved
survival for hepatocellular carcinoma but poor survival for biliary
tract cancers remains unchanged. Eur J Surg Oncol. 45:1660–1667.
2019. View Article : Google Scholar
|
|
7
|
Groot Koerkamp B, Wiggers JK, Allen PJ,
Besselink MG, Blumgart LH, Busch OR, Coelen RJ, D'Angelica MI,
DeMatteo RP, Gouma DJ, et al: Recurrence rate and pattern of
perihilar cholangiocarcinoma after curative intent resection. J Am
Coll Surg. 221:1041–1049. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Komaya K, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Mizuno T, Yamaguchi J and Nagino M: Recurrence after
curative-intent resection of perihilar cholangiocarcinoma: Analysis
of a large cohort with a close postoperative follow-up approach.
Surgery. 163:732–738. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cambridge WA, Fairfield C, Powell JJ,
Harrison EM, Søreide K, Wigmore SJ and Guest RV: Meta-analysis and
meta-regression of survival after liver transplantation for
unresectable perihilar cholangiocarcinoma. Ann Surg. 273:240–250.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spolverato G, Kim Y, Alexandrescu S,
Marques HP, Lamelas J, Aldrighetti L, Clark Gamblin T, Maithel SK,
Pulitano C, Bauer TW, et al: Management and outcomes of patients
with recurrent intrahepatic cholangiocarcinoma following previous
curative-intent surgical resection. Ann Surg Oncol. 23:235–243.
2016. View Article : Google Scholar
|
|
11
|
Forner A, Vidili G, Rengo M, Bujanda L,
Ponz-Sarvisé M and Lamarca A: Clinical presentation, diagnosis and
staging of cholangiocarcinoma. Liver Int. 39 (Suppl 1):S98–S107.
2019. View Article : Google Scholar
|
|
12
|
Banales JM, Marin JJG, Lamarca A,
Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen
JB, Braconi C, et al: Cholangiocarcinoma 2020: The next horizon in
mechanisms and management. Nat Rev Gastroenterol Hepatol.
17:557–588. 2020. View Article : Google Scholar
|
|
13
|
Lollo G, Matha K, Bocchiardo M, Bejaud J,
Marigo I, Virgone-Carlotta A, Dehoux T, Rivière C, Rieu JP,
Briançon S, et al: Drug delivery to tumours using a novel 5-FU
derivative encapsulated into lipid nanocapsules. J Drug Target.
27:634–645. 2019. View Article : Google Scholar
|
|
14
|
Lee JJ, Beumer JH and Chu E: Therapeutic
drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol.
78:447–464. 2016. View Article : Google Scholar
|
|
15
|
Yang CG, Ciccolini J, Blesius A, Dahan L,
Bagarry-Liegey D, Brunet C, Varoquaux A, Frances N, Marouani H,
Giovanni A, et al: DPD-based adaptive dosing of 5-FU in patients
with head and neck cancer: Impact on treatment efficacy and
toxicity. Cancer Chemother Pharmacol. 67:49–56. 2011. View Article : Google Scholar
|
|
16
|
Bell BM, Kirk ID, Hiltbrunner S,
Gabrielsson S and Bultema JJ: Designer exosomes as next-generation
cancer immunotherapy. Nanomedicine. 12:163–169. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Watson DC, Bayik D, Srivatsan A,
Bergamaschi C, Valentin A, Niu G, Bear J, Monninger M, Sun M,
Morales-Kastresana A, et al: Efficient production and enhanced
tumor delivery of engineered extracellular vesicles. Biomaterials.
105:195–205. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Vojtech L, Woo S, Hughes S, Levy C,
Ballweber L, Sauteraud RP, Strobl J, Westerberg K, Gottardo R,
Tewari M and Hladik F: Exosomes in human semen carry a distinctive
repertoire of small non-coding RNAs with potential regulatory
functions. Nucleic Acids Res. 42:7290–7304. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhong J, Xia B, Shan S, Zheng A, Zhang S,
Chen J and Liang XJ: High-quality milk exosomes as oral drug
delivery system. Biomaterials. 277:1211262021. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dai J, Su Y, Zhong S, Cong L, Liu B, Yang
J, Tao Y, He Z, Chen C and Jiang Y: Exosomes: Key players in cancer
and potential therapeutic strategy. Signal Transduct Target Ther.
5:1452020. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Liang Y, Duan L, Lu J and Xia J:
Engineering exosomes for targeted drug delivery. Theranostics.
11:3183–3195. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang J, Chen D and Ho EA: Challenges in
the development and establishment of exosome-based drug delivery
systems. J Control Release. 329:894–906. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gatti S, Bruno S, Deregibus MC, Sordi A,
Cantaluppi V, Tetta C and Camussi G: Microvesicles derived from
human adult mesenchymal stem cells protect against
ischaemia-reperfusion-induced acute and chronic kidney injury.
Nephrol Dial Transplant. 26:1474–1483. 2011. View Article : Google Scholar
|
|
24
|
Farooqi AA, Desai NN, Qureshi MZ,
Librelotto DRN, Gasparri ML, Bishayee A, Nabavi SM, Curti V and
Daglia M: Exosome biogenesis, bioactivities and functions as new
delivery systems of natural compounds. Biotechnol Adv. 36:328–334.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Jeppesen DK, Fenix AM, Franklin JL,
Higginbotham JN, Zhang Q, Zimmerman LJ, Liebler DC, Ping J, Liu Q,
Evans R, et al: Reassessment of exosome composition. Cell.
177:428–445.e18. 2019. View Article : Google Scholar
|
|
26
|
Longley DB, Harkin DP and Johnston PG:
5-fluorouracil: Mechanisms of action and clinical strategies. Nat
Rev Cancer. 3:330–338. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wei H, Chen J, Wang S, Fu F, Zhu X, Wu C,
Liu Z, Zhong G and Lin J: A nanodrug consisting of doxorubicin and
exosome derived from mesenchymal stem cells for osteosarcoma
treatment in vitro. Int J Nanomedicine. 14:8603–8610. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liang G, Zhu Y, Ali DJ, Tian T, Xu H, Si
K, Sun B, Chen B and Xiao Z: Engineered exosomes for targeted
co-delivery of miR-21 inhibitor and chemotherapeutics to reverse
drug resistance in colon cancer. J Nanobiotechnology. 18:102020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen
I, Klyachko NL, Kabanov AV and Batrakova EV: Engineering
macrophage-derived exosomes for targeted paclitaxel delivery to
pulmonary metastases: In vitro and in vivo evaluations.
Nanomedicine. 14:195–204. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lamichhane TN, Jeyaram A, Patel DB,
Parajuli B, Livingston NK, Arumugasaamy N, Schardt JS and Jay SM:
Oncogene knockdown via active loading of small RNAs into
extracellular vesicles by sonication. Cell Mol Bioeng. 9:315–324.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Thakur A, Sidu RK, Zou H, Alam MK, Yang M
and Lee Y: Inhibition of glioma cells' proliferation by
doxorubicin-loaded exosomes via microfluidics. Int J Nanomedicine.
15:8331–8343. 2020. View Article : Google Scholar : PubMed/NCBI
|
